三个皮匠报告—— 严选型全行业研究报告分享下载平台,您的专属行业智库!
欢迎来到三个皮匠报告!
登录
帮助中心
首页
最新
研搜
BETA
合集
英文
会议
数据
财报库
政策库
自研报告
入驻
您的当前位置:
首页
>
行业数据
>
安进的CD3/DLL3双抗Tarlatamab于2024年5月获FDA加速批准上市
安进的CD3/DLL3双抗Tarlatamab于2024年5月获FDA加速批准上市
行业数据
下载Excel
下载图片
原图定位
图片属性
图片格式:PNG
图片大小:89KB
图片尺寸:1743*456
同报告图片
/
4
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
所属报告:
生物制品行业深度报告:DLL3SCLC高表达明星靶点多款国产新药未来可期-241230(17页).pdf
打包全文图表
相关数据
到2040年美国FDA批准的中国原创新药占比
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
收藏
行业数据
2026-06-11
原图定位
查看详情
美国FDA各年度批准NME药物与生物药数量
收藏
行业数据
2026-05-25
原图定位
查看详情
美国FDA药物评价与研究中心受理的IND申请
收藏
行业数据
2026-04-08
原图定位
查看详情
图表11FDA获批KRASG12C抑制剂的全球销售额(百万美元)
收藏
行业数据
2026-02-25
原图定位
查看详情
图 26 美国食品和药物管理局(FDA)在2020年开始实施RACE法案,以确保更多癌症药物试验包括儿童人群
收藏
行业数据
2026-02-13
原图定位
查看详情
**TABLE 5. FDA-approved Immunotherapeutics to Treat Pediatric Cancers (2015–2025)**
收藏
行业数据
2026-02-13
原图定位
查看详情
**TABLE 4 FDA-approved Molecularly Targeted Therapies to Treat Pediatric Cancers (2015–2025)**
收藏
行业数据
2026-02-13
原图定位
查看详情
表 5 FDA批准的免疫治疗药物用于治疗儿科癌症(2015–2025)
收藏
行业数据
2026-02-13
原图定位
查看详情
Figure 2 FDA-approved therapeutics with CDx, including novel oncological therapies (1997-2024)
收藏
行业数据
2026-02-13
原图定位
查看详情
表4 FDA批准的分子靶向疗法用于治疗儿童癌症(2015–2025)
收藏
行业数据
2026-02-13
原图定位
查看详情
2018-2024年FDA批准的创新抗体药物分类(个)
fCDliIbnsbsgICB8IOaVsOmHj++8iOS4qu+8iSB8IOWNoOavlCAgIHwKfCAtLS0tLS0gfCAtLS0tLS0tLS0tIHwgLS0tLS0tIHwKfCDltYzlkIjkvZMgfCAzICAgICAgICAgIHwgNC42JSAgIHwKfCDlhajkurrmupAgfCAyMiAgICAgICAgIHwgMzMuOCUgIHwKfCDkurrmupDljJYgfCA0MCAgICAgICAgIHwgNjEuNSUgIHwKCui1hOaWmeadpea6kO+8muWFrOWPuOaLm+iCoeS5pu+8jOW8l+iLpeaWr+eJueaymeWIqeaWh++8jOWbveazsOa1t+mAmuivgeWIuOeglOeptg==
收藏
行业数据
2026-01-27
原图定位
查看详情
2018-2024年FDA批准的全人源抗体制备技术分
fCDmioDmnK/nsbvliKsgICAgICAgfCDmlbDph4/vvIjkuKrvvIkgfAp8LS0tLS0tLS0tLS0tLS0tLXwtLS0tLS0tLS0tLS18Cnwg6L2s5Z+65Zug5bCP6byg5oqA5pyvIHwgOSAgICAgICAgICB8Cnwg5Zms6I+M5L2T5bGV56S65oqA5pyvIHwgNyAgICAgICAgICB8Cnwg5YW25a6D5oqA5pyvICAgICAgIHwgNiAgICAgICAgICB8CgrotYTmlpnmnaXmupDvvJrlhazlj7jmi5vogqHkuabvvIzlvJfoi6Xmlq/nibnmspnliKnmlofvvIzlm73ms7DmtbfpgJror4HliLjnoJTnqbY=
收藏
行业数据
2026-01-27
原图定位
查看详情
FDA拟禁用合成色素种类在欧盟和中国使用情况
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
收藏
行业数据
2026-01-15
原图定位
查看详情
2018-2024各年NMPA及FDA合批准的抗
fCDlubTku70gfCDmipfkvZPoja/mlbDph4/vvIjkuKrvvIkgfAp8LS0tLS0tfC0tLS0tLS0tLS0tLS0tLS0tLXwKfCAyMDE4IHwgMjAgICAgICAgICAgICAgICB8CnwgMjAxOSB8IDE2ICAgICAgICAgICAgICAgfAp8IDIwMjAgfCAxNiAgICAgICAgICAgICAgIHwKfCAyMDIxIHwgMjEgICAgICAgICAgICAgICB8CnwgMjAyMiB8IDIxICAgICAgICAgICAgICAgfAp8IDIwMjMgfCAyMyAgICAgICAgICAgICAgIHwKfCAyMDI0IHwgMzIgICAgICAgICAgICAgICB8CgrotYTmlpnmnaXmupDvvJrnmb7lpaXotZvlm77mi5vogqHkuabvvIxGREHvvIxDREXvvIzlvJfoi6Xmlq/nibnmspnliKnmlofvvIzlm73ogZTmsJHnlJ/or4HliLg=
收藏
行业数据
2026-01-05
原图定位
查看详情
2018-2024FDA批准的创新抗体药分类
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
收藏
行业数据
2026-01-05
原图定位
查看详情
最新数据
全球全年龄段奶粉市场规模(亿美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球酸奶及发酵乳制品市场规模(亿美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球药用级益生菌市场规模(百万美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球益生菌膳食补充剂市场规模及增速
收藏
行业数据
2026-07-30
原图定位
查看详情
全球拥有AKK专利菌株的核心企业
收藏
行业数据
2026-07-30
原图定位
查看详情
DLL3 双抗/多抗可以与癌细胞上的 DLL3 与 T 细胞上的 CD3 相结合,将 T细胞聚集到 SCLC 肿瘤细胞周边,激活 T 细胞来杀伤肿瘤细胞。2024 年 5 月,安进的CD3/DLL3 双抗 Tarlatamab获 FDA加速批准,用于治疗在铂类化疗期间或之后病情进展的广泛期 SCLC,这也是目前首个获批用于治疗 SCLC的DLL3靶向 TCE双抗。
行业数据
原图定位
当前图表所属:
生物制品行业深度报告:DLL3SCLC高表达明星靶点多款国产新药未来可期-241230(17页).pdf
随着DLL3领域未来越来越多管线布局及早研数据读出,赛道景气度预计持续提升,相关标的有望受益
国内多家上市企业围绕DLL3靶点进行布局
多因素导致Rova-T临床研发失败
安进的CD3/DLL3双抗Tarlatamab于2024年5月获FDA加速批准上市
下载图片或Excel,需升级至尊VIP会员或「预见者」VIP
立即去升级
客服
商务合作
小程序
服务号
回到顶部
折叠
微信扫码登录
微信扫码登录
双重福利,扫码领取!
关注公众号『三个皮匠报告』,免费领取报告
1.100+最新优质行业报告
2.每周免费精选报告分享
手机快捷登录
账号登录
记住密码
忘记密码?
验证即登录,未注册将自动创建账号
获取验证码
收不到验证码注意事项
登录代表您已阅读并同意
《三个皮匠服务条款》